2024
The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions
Alameddine D, Damara F, Pinto Rodriguez P, Huttler J, Slade M, Arhuidese I, Aboian E, Ochoa Chaar C. The Use and Impact of Cilostazol on Patients Undergoing Endovascular Peripheral Interventions. Annals Of Vascular Surgery 2024, 103: 47-57. PMID: 38387798, DOI: 10.1016/j.avsg.2023.12.071.Peer-Reviewed Original ResearchImpact of cilostazolPeripheral vascular interventionsPeripheral arterial diseaseTreatment of intermittent claudicationRates of long-term mortalityPeripheral vascular interventional proceduresKaplan-Meier methodCongestive heart failureLong-term mortalityLong-term outcomesEndovascular peripheral interventionsRenal complicationsPatient demographicsBaseline characteristicsHeart failureDiabetes mellitusArtery diseaseIntermittent claudicationCilostazolPatientsVascular interventionsPeripheral interventionsClaudicationOutcomesIntervention
2021
Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry
Lee M, Ahmed ZV, Huang J, Jelani QU, Aboian E, Peri-Okonny PA, Smolderen KG, Mena-Hurtado C. Real-world antithrombotic treatment variability in patients undergoing peripheral vascular intervention: Insights from the VQI registry. American Heart Journal 2021, 244: 31-35. PMID: 34688650, DOI: 10.1016/j.ahj.2021.10.186.Peer-Reviewed Original ResearchConceptsPeripheral vascular interventionsDual antiplatelet therapySingle antiplatelet therapyAntiplatelet therapyVascular interventionsOptimal medical therapyNew trial dataAntithrombotic prescriptionMedical therapyPrescription ratesProvider factorsVQI registryTrial dataTherapyHealth systemPatientsTreatment variabilityPractice levelInterventionHigh levelsRegistryPhysicians